Gritstone

-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older…

<!-- Name:DistributionId Value:8802285 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8748513 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today…

-- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells…

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines,…

-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS)…

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious…

GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants…

CEPI to fund Gritstone’s work on second-generation vaccines against SARS-CoV-2, the virus causing COVID-19, including a clinical trial in South Africa and manufacturing…